Inhalable Nanocrystal-in-Microparticle of Linezolid in Pulmonary Tuberculosis

Background

Tuberculosis (TB) remains a major global health challenge, necessitating the development of advanced pulmonary drug delivery systems to improve therapeutic efficacy. Linezolid (LZD), a second-line oxazolidinone antibiotic, is effective against multidrug-resistant Mycobacterium tuberculosis but is associated with systemic adverse effects when administered orally for prolonged periods.